Buprenorphine/naloxone (Suboxone) comprises the partial mu-opioid receptor agonist buprenorphine in combination with the opioid antagonist naloxone in a 4 : 1 ratio. When buprenorphine/naloxone is taken sublingually as prescribed, the naloxone exerts no clinically significant effect, leaving the opioid agonist effects of buprenorphine to predominate. However, when buprenorphine/naloxone is pare...

mu-Opioid receptor (MOR) agonists represent the gold standard for the treatment of severe pain but may paradoxically also enhance pain sensitivity, that is, lead to opioid-induced hyperalgesia (OIH). We show that abrupt withdrawal from MOR agonists induces long-term potentiation (LTP) at the first synapse in pain pathways. Induction of opioid withdrawal LTP requires postsynaptic activation of h...

opioid therapy often results in uncomfortable signs and symptoms of withdrawal. The severity of these symptoms can fluctuate among patients, even among those with similar body mass index, gender, and dosage. Several theories have been proposed regarding the contribution of noradrenergic pathways in the expression of opioid withdrawal.1 In the central nervous system, the major clustering of nore...

background:naltrexone is a competitive opioid receptor antagonist blocking the euphoric effects of exogenous opioids. when used concomitantly with opioids, naltrexone causes severe withdrawal symptoms.the main aim of the study is to determine the symptomatology and outcome of patients who consumed naltrexone in conjunction with an opioid substance. methods:this cross-sectional study was perform...

objective: withdrawal symptoms are a main reason of continuous use of opioid. this study compares the efficacy of augmentation of amantadine with clonidine in decreasing opioid withdrawal symptoms. methods: this double-blind randomized clinical trial was carried out in the detoxification and rehabilitation inpatient ward at razi hospital, tabriz, iran during 2012. the patients were randomly ass...

Background: Buprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics. Aim of the present study was to compare the efficiency of buprenorphine with buprenorphine/naloxone in short-term detoxification in a group of Iranian male opioid-dependent patients. Methods:A double-blind trial was carried out on a gro...

INTRODUCTION Patients who are discharged following surgery on an oral opioid, and who have taken the drug for 2 or more weeks often experience withdrawal symptoms when they try to discontinue the drug. CASE REPORT Three weeks after discharge, a 44-year-old female patient decided to reduce her oxycodone (OxyContin(®)) dosage from 20 mg three times a day to 20 mg two times a day. She experience...

Preclinical evidence suggests that opioid withdrawal induces central sensitization (CS) that is maintained by supraspinal contributions from the descending pain modulatory system (DPMS). Here, in healthy human subjects we use functional magnetic resonance imaging to study the supraspinal activity during the withdrawal period of the opioid remifentanil. We used a crossover design and thermal sti...